论文部分内容阅读
动脉粥样硬化性心血管疾病仍然是全球范围内人类死亡的主要原因之一.血脂异常是动脉粥样硬化最重要的危险因素.他汀类药物是降低血清胆固醇最有效的药物之一,同时能够降低心血管事件风险;但接受最佳剂量他汀治疗的患者仍然存在心血管事件残余风险.血清三酰甘油过高或高密度脂蛋白胆固醇过低可能是导致心血管事件残余风险的主要危险因素.与单独应用他汀类药物相比,他汀类药物与贝特类药物联用可能会进一步降低混合型高脂血症患者血清低密度脂蛋白胆固醇水平,并同时降低三酰甘油和升高高密度脂蛋白胆固醇,进而可能降低心血管事件风险.然而,某些他汀类药物与贝特类药物联用也有安全性方面的担忧.现将近年来的相关研究及临床指南进行复习,着重从他汀类药物与贝特类药物联合应用的有效性和安全性方面进行综述,旨在对临床常见的混合型高脂血症患者的治疗提供依据.“,”Arteriosclerotic cardiovascular disease is still one of the leading causes of death worldwide.Dyslipidemia is the most important risk factor for atherosclerosis.Statins are one of the most effective drugs to reduce cholesterol and risk of cardiovascular events. However,patients who received the optimal dose of statin therapy still have residual cardiovascular risk.The main risk factors leading to the residual risk of cardiovascular events are extremely high serum triglyceride or extremely low -high density lipoprotein cholesterol.Compared with the single application of statins,the combination therapy of statins and fibrates may further reduce the low-density lipoprotein cholesterol levels of serum in patients with mixed hyperlipidemia,and decrease TG and increase HDL-C,which may reduce the risk of cardiovascular events.However,the combination of certain statins and fibrates is associated with safety concerns.This paper will review the recent research and clinical guidelines,focusing on the effectiveness and safety of combination of statins and fibrates,which provide a basis for treatment of common hyperlipidemia patients.